1. Home
  2. SEDG vs SNDX Comparison

SEDG vs SNDX Comparison

Compare SEDG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SolarEdge Technologies Inc.

SEDG

SolarEdge Technologies Inc.

HOLD

Current Price

$33.59

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$22.12

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEDG
SNDX
Founded
2006
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
SEDG
SNDX
Price
$33.59
$22.12
Analyst Decision
Hold
Strong Buy
Analyst Count
19
13
Target Price
$28.20
$80.69
AVG Volume (30 Days)
3.3M
1.1M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
78.26
11.56
EPS
N/A
N/A
Revenue
$1,184,444,000.00
$172,352,000.00
Revenue This Year
$16.93
$113.52
Revenue Next Year
$12.92
$52.49
P/E Ratio
N/A
N/A
Revenue Growth
31.39
627.84
52 Week Low
$11.00
$8.59
52 Week High
$48.60
$22.73

Technical Indicators

Market Signals
Indicator
SEDG
SNDX
Relative Strength Index (RSI) 44.31 59.12
Support Level $30.04 $19.46
Resistance Level $33.97 $22.33
Average True Range (ATR) 3.54 1.01
MACD -0.61 0.14
Stochastic Oscillator 9.74 81.84

Price Performance

Historical Comparison
SEDG
SNDX

About SEDG SolarEdge Technologies Inc.

SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: